Immunoassays in Multiplex for Personalized Medicine

Jens Göpfert

Molecular Diagnostics Europe
London, UK

Natural and Medical Sciences Institute at the University of Tübingen
Drug Safety

(Critical Path Initiative)

Predictive Safety Testing Consortium

RBM
RULES • BASED MEDICINE
Antibody based Biomarker assays

- FDA Critical Path Initiative
- Predictive Safety Testing Consortium (PSTC)
- 7 urinary biomarkers for drug induced kidney injury submitted for FDA approval

*Nature Biotechnology 28, May 2010*
Antibody based Biomarker assays

- Rat Nephrotoxicity Panel
- Rules Base Medicine / Luminex Array

1. **β-2 Microglobulin**
2. Calbindin
3. **Clusterin**
4. **Cystatin-C**
5. Epidermal Growth Factor (EGF)
6. Glutathione S-Transferase-alpha (GST-α)
7. Glutathione S-Transferase-pi (GST-Π)
8. **Kidney injury molecule 1 (KIM1)**
9. Neutrophil Gelatinase Associated Lipocalin (NGAL)
10. Osteopontin
11. Tissue Inhibitor of Metalloproteinase-1 (TIMP-1)
12. Vascular Endothelial Growth Factor (VEGF)
Kidney Toxicity Standard

Proximal Tubules
- Alpha-GST
- KIM-1
- Clusterin
- Osteopontin
- β-2-microglobulin
- Calbindin d28
- NAG
- TIMP-1

Distal Tubules
- mu GST
- KIM-1
- Clusterin
- Osteopontin
- TIMP-1

Glomeruli
- β-2-microglobulin
- Podocin

http://www.uic.edu/classes/bios/bios100/lecturesf04am/kidney01a.jpg
The Innovative Medicine Initiative
Safer & Faster Evidence Based Translation project

Qualification of new specific and sensitive safety biomarkers for drug-induced

Kidney

Liver

Vascular injury to improve safety of drug development

Academia

 Advisors

 SMEs

 EFPIA

 Collaborators
Drug safety: room for improvement
The economic perspective

- Around 90% of compounds entering clinical development fail

- 30% of these failures are due to clinical safety and toxicology

Kola et al. (2004), Nat Rev Drug Discovery ; 3: 711-15
The Innovative Medicine Initiative
The SAFE-T project:

- Literature
- Databases
- SAFE-T sources

Select

- Healthy volunteers
- Patients with x-disease
- Patients with non-x disease
- Patients on x-toxic drugs

Select

Samples

Biomarker step 1 list

Evaluation

Biomarker step 2 list

Regulatory advice

Assay availability / development

Exploratory phase

Biomarker step 3 list

Assay / stat analysis / select specific+sensitive BMs

Biomarker step 4 list

Assay / stat analysis / select specific+sensitive BMs

Confirmatory phase

Regulatory advice

Assay / stat analysis / select specific+sensitive BMs

Biomarker final list

Submit to health authorities

Regulatory approval

Background variability

Thresholds (ROCs)

Qualification
The Innovative Medicine Initiative
The SAFE-T project:

List of Biomarker candidates

Biomarker step 1 list

Literature
Databases
SAFE-T sources

Healthy volunteers
Patients with x- disease
Patients with non-x disease
Patients on x-toxic drugs

List of Biomarker candidates

Biomarker step 2 list

Selected

Technical Validation

Clinical Validation

Exploratory phase

Assay / stat analysis / select specific+sensitive BMs

Biomarker step 3 list

Regulatory advice

Background variability

Thresholds (ROCs)

Confirmatory phase

Assay / stat analysis / select specific+sensitive BMs

Biomarker final list

Regulatory advice

Qualification

Submit to health authorities

Regulatory approval

Matheis et al., DDT, 2011, 16 (13-14)
DILI biomarker candidates selected for qualification

- **Drug Induced Liver Injury** is a rare event, sample availability is limited

<table>
<thead>
<tr>
<th>Serum or Plasma Marker</th>
<th>Assays</th>
<th>Liver specificity</th>
<th>Human data</th>
<th>Pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>miRNA 122</td>
<td>RNA / QPCR</td>
<td>highly specific</td>
<td>yes</td>
<td>heptocellular damage</td>
</tr>
<tr>
<td>albumin mRNA</td>
<td></td>
<td>highly specific</td>
<td>yes</td>
<td>heptocellular damage</td>
</tr>
<tr>
<td>Microglobulin precursor (Ambp) mRNA</td>
<td></td>
<td>highly specific</td>
<td>yes</td>
<td>heptocellular damage</td>
</tr>
<tr>
<td>High mobility group box 1 (acetylated vs. non-acetylated)</td>
<td></td>
<td>not specific</td>
<td>yes</td>
<td>cholestasis</td>
</tr>
<tr>
<td>Conjugated/unconjugated bile acids</td>
<td></td>
<td>highly specific</td>
<td>only in tissue</td>
<td>heptocellular damage</td>
</tr>
<tr>
<td>F-protein (HPPD)</td>
<td>LC-MS</td>
<td>highly specific</td>
<td>yes</td>
<td>heptocellular damage</td>
</tr>
<tr>
<td>Arginase 1</td>
<td></td>
<td>highly specific</td>
<td>yes</td>
<td>heptocellular damage</td>
</tr>
<tr>
<td>Keratin 18 (caspase cleaved &amp; intact)</td>
<td></td>
<td>not specific</td>
<td>yes</td>
<td>heptocellular damage</td>
</tr>
<tr>
<td>Alpha fetoprotein (AFP)</td>
<td></td>
<td>specific</td>
<td>yes</td>
<td>heptocellular damage</td>
</tr>
<tr>
<td>Regucalcin (RGN)</td>
<td></td>
<td>specific</td>
<td>only in tissue</td>
<td>heptocellular damage</td>
</tr>
<tr>
<td>Glutathione S-Transferase (GST-alpha)</td>
<td></td>
<td>specific</td>
<td>yes</td>
<td>heptocellular damage</td>
</tr>
<tr>
<td>ST6gal I</td>
<td>Immunoassay</td>
<td>specific</td>
<td>yes</td>
<td>inflammation</td>
</tr>
<tr>
<td>Osteopontin</td>
<td></td>
<td>not specific</td>
<td>yes</td>
<td>inflammation</td>
</tr>
<tr>
<td>Colony stimulating factor receptor (CSF1R)</td>
<td></td>
<td>not specific</td>
<td>yes</td>
<td>inflammation</td>
</tr>
<tr>
<td>LECT2</td>
<td></td>
<td>not specific</td>
<td>yes</td>
<td>inflammation</td>
</tr>
<tr>
<td>Paraoxonase 1 (PON1)</td>
<td></td>
<td>not specific</td>
<td>yes</td>
<td>steatosis</td>
</tr>
<tr>
<td>Prothrombin</td>
<td></td>
<td>not specific</td>
<td>yes</td>
<td>steatosis</td>
</tr>
<tr>
<td>Glutamate dehydrogenase (GLUD, GLDH)</td>
<td></td>
<td>specific</td>
<td>yes</td>
<td>heptocellular damage</td>
</tr>
<tr>
<td>Sorbitol dehydrogenase (SDH)</td>
<td></td>
<td>specific</td>
<td>yes</td>
<td>heptocellular damage</td>
</tr>
</tbody>
</table>

Composite disease markers to be assessed in addition: ActiTest™, Fibrotest™, SteatoTest™
SAFE-T

- **DIKI**
  - 21 biomarkers listed for evaluation in SAFE-T
  - For some markers results available from preclinical experiments (PSTC)
  - All biomarkers are now tested with samples from clinical studies

- **DIVI**
  - Not much known about potential biomarkers
  - 35 potential biomarkers were chosen for evaluation

- Identified biomarkers will not only be applied in drug development, but might also be used for personalized medicine.